Nucleic acid-based medications such as mRNA vaccines offer tremendous potential for medicine and are opening up new therapeutic approaches. These active ingredients must be enclosed inside nanoparticles to ensure that they get to where they are needed inside the body’s cells.
The Fraunhofer Institute for Production Systems and Design Technology IPK and FDX Fluid Dynamix GmbH have worked together to develop a technology platform for the production of nanoparticles that can achieve particle quality and stability at levels previously out of reach: FDmiX, short for Fraunhofer Dynamic Mixing Technologies. Swiss chemical and pharmaceutical company Lonza has now licensed the technology for its own good manufacturing practice (GMP) production activities.
RNA and DNA, both nucleic acids, are not only found in cells; they can also be components of medications. One common example widely known from the coronavirus pandemic is mRNA vaccines.
Medical professionals the world over are very hopeful about nucleic acid-based active ingredients, which offer potential as therapies for diseases that were previously difficult to treat, including some forms of cancer. However, safely and effectively transporting these sensitive nucleic acids to the cells, where the messages they carry can be translated into proteins, has proven to be a significant challenge thus far.
A protective envelope is needed to get the sensitive active ingredient into the cells. These nanoparticles are produced using fluid mixing processes. Very thorough, rapid mixing is necessary to produce particles of the requisite quality. Impinging jet mixers (also known as T-mixers or Y-mixers) are available for industrial-scale applications. They enable high throughput, but at the expense of mixing quality.
Better, faster mixing
In the Fraunhofer Dynamic Mixing Technologies (FDmiX) platform, Fraunhofer IPK and FDX Fluid Dynamix GmbH have managed to bridge the gap between mixing quality and throughput. The FDmiX platform allows for consistently high mixing quality at any scale, from the lab right up to mass production. It has already successfully passed tests aimed at production of lipid and polymer nanoparticles and of nanoemulsions.
As extensive testing has shown, the mixing quality of the FDmiX technology platform is superior to the systems that have been available to date, enabling production of particles at previously unattainable levels of quality.
The system is also impressive in terms of its scaling capability, as encapsulation can take place with volume streams ranging from 5 ml/min to 1.5 l/min without affecting the particle properties.
Lonza, a global development and production partner to the pharmaceutical, biotech, and neutraceuticals markets, has licensed the patented FDmiX technology and is already using it.
“Human cells defend themselves against foreign genetic material. That’s why the mRNA active ingredients have to be enclosed inside nanoparticles. So the particles act as a protective envelope, encapsulating the substance until it has entered the cell inside the body,” says Christoph Hein, head of the Ultra- and High-precision Technology division at Fraunhofer IPK in Berlin.
To be able to produce the nanoparticles, the active ingredient dissolved in a buffer has to be mixed with another solution, such as a lipid solution. Once the two liquids have been combined, lipid nanoparticles are formed which in turn form a lipid envelope around the active ingredient.
“With the FDmiX platform, we can produce significantly smaller and more homogeneous particles and even adjust their size. FDmiX lets us produce mixtures of a previously unattainable level of homogeneity with very short mixing times. That’s relevant because the mixing quality not only determines the quality of the nanoparticles, but ultimately also how effective they are.”
Clever nozzle design leads to homogeneously mixed nanoparticles
But how can a high and consistent mixing quality be combined with throughput? The centerpiece of the FDmiX platform is an OsciJet nozzle from FDX Fluid Dynamix GmbH.
Inside the nozzle, a jet of liquid is positioned on one of the sides of the main chamber. Before leaving the nozzle, a small part of the jet is deflected into a side channel. At the end of the side channel, it meets the main jet again and pushes it to the other side. This causes the main jet to oscillate continuously from one side to the other at a high frequency.
In this way, the jet of lipid solution oscillating through the nozzle meets the stream of the mRNA active ingredient at a perpendicular angle, creating a homogeneous mixture with nanoparticles of uniform size.
In tests of conventional impinging mixers (also known as T-mixers or Y-mixers), by contrast, the lipid solution and mRNA active ingredient collide before flowing together through the same channel. This creates a dynamic vortex, resulting in inhomogeneous particles of lower quality.
“In encapsulation tests on mRNA in lipid nanoparticles using different mixers and flow rates, FDmiX generated smaller particles with significantly lower size distribution compared to a T-mixer at the same flow rate,” Hein explains.
In tests, the project partners produced nanoparticles about 10% to 20% smaller than those produced using a T-mixer. They also had significantly smaller size distribution and high encapsulation efficiency and particle integrity.
Large quantities of nanoparticles are needed during the clinical phase and the subsequent production stage. Here as well, the technology from Fraunhofer IPK and FDX Fluid Dynamix GmbH is impressive: The two project partners developed and tested mixers for various pressure and flow rates. The smallest mixers (FDmiX XS) can work at flow rates under 5 milliliters per minute, while the largest (FDmiX XL) can work at more than 1.5 liters per minute.
Broad range of applications for FDmiX nanoparticles
The nanoparticles produced in this way can be used for a wide range of applications, well beyond encapsulation of mRNA and stabilization of vaccines.
For example, this technology can also be used in cardiology for cardiac catheter coatings. When a balloon catheter is expanded during an examination, nanoparticles are absorbed into the arterial wall, preventing new deposits from forming there. This can help to prevent stenosis, or narrowing of the blood vessels.
Nanoparticles are also used in tumor therapy, and the molecules may also be helpful in treating neurodegenerative diseases such as Alzheimer’s and other forms of dementia.
Provided by Fraunhofer-Gesellschaft
![](https://www.nanoappsmedical.com/wp-content/uploads/2017/05/spacer.jpg)
News
Ethics in Nanomedicine: Key Issues and Principles
Nanomedicine, a branch of nanotechnology, is revolutionizing healthcare by enabling the manipulation of materials at the nanoscale to diagnose, treat, and prevent diseases. Unlike traditional treatments, nanoparticles (NPs) are highly precise in targeting diseased [...]
A call for robust H5N1 influenza preparedness and response
As the global threat of H5N1 influenza looms with outbreaks across species and continents including the U.S., three international vaccine and public health experts say it is time to fully resource and support a [...]
Mucosal COVID-19 boosters outperform mRNA shots in preventing upper airway infections
In a recent study published in Nature Immunology, a team of researchers from the United States used non-human primate models to compare the protection conferred by an intramuscular booster dose of the bivalent messenger ribonucleic acid [...]
How Space Travel Really Changes Astronauts – From the Inside Out
International team reveals previously unknown effects on physiology that could shape the future of long-duration space missions. Researchers have discovered significant changes in the gut microbiome due to spaceflight, which affects host physiology and [...]
Breakthrough in blood stem cell development offers hope for leukemia and bone marrow failure
Melbourne researchers have made a world first breakthrough into creating blood stem cells that closely resemble those in the human body. And the discovery could soon lead to personalized treatments for children with leukemia [...]
Scientists Develop Game-Changing Needle-Free COVID-19 Intranasal Vaccine
A new mucosal COVID-19 vaccine poised to revolutionize the delivery process is especially beneficial for those with a fear of needles. A next-generation COVID-19 mucosal vaccine is set to be a game-changer not only when delivering [...]
Scientists Develop All-in-One Solution To Catch and Destroy “Forever Chemicals”
A new water treatment system developed by UBC researchers efficiently removes and destroys PFAS pollutants using a dual-action catalyst, offering a sustainable and cost-effective solution for water purification challenges. Chemical engineers at the University of [...]
New method accelerates drug discovery from years to months
Researchers from the University of Cincinnati College of Medicine and Cincinnati Children's Hospital have found a new method to increase both speed and success rates in drug discovery. The study, published Aug. 30 in [...]
A new smart mask analyzes your breath to monitor your health
Your breath can give away a lot about you. Each exhalation contains all sorts of compounds, including possible biomarkers for disease or lung conditions, that could give doctors a valuable insight into your health. [...]
Study reveals the role of blood clotting in COVID-19
In a study that reshapes what we know about COVID-19 and its most perplexing symptoms, scientists have discovered that the blood coagulation protein fibrin causes the unusual clotting and inflammation that have become hallmarks [...]
A Novel Cancer Vaccine Combining Nano-11 and ADU-S100
In a recent article published in npj Vaccines, researchers detailed the development of a novel cancer vaccine that combines a plant-derived nanoparticle adjuvant, Nano-11, with a clinically tested STING agonist, ADU-S100. The primary objective was [...]
AI spots cancer and viral infections with nanoscale precision
Researchers have developed an artificial intelligence which can differentiate cancer cells from normal cells, as well as detect the very early stages of viral infection inside cells. The findings, published today in a study [...]
Tiny shards of plastic are increasingly infiltrating our brains, study says
Human brain samples collected at autopsy in early 2024 contained more tiny shards of plastic than samples collected eight years prior, according to a preprint posted online in May. A preprint is a study which has not yet [...]
Scientists Have Discovered Strange DNA in Our Brains – and It Could Be Shortening Our Lives
According to the research, these mitochondrial DNA insertions could be linked to early death. Mitochondria in brain cells frequently insert their DNA into the nucleus, potentially impacting lifespan, as those with more insertions were found to [...]
Watch Out After a Hospital Stay: You Could Be Exposing Your Family to Superbugs
Research indicates hospitals contribute to the local spread of antibiotic-resistant infections. A recent study published in the journal Infection Control & Hospital Epidemiology by the Society for Healthcare Epidemiology of America suggests that family members of [...]
Molecular Trickery: How COVID-19 Silently Sabotages the Human Immune System
Researchers have discovered that SARS-CoV-2 manipulates the human immune system by forcing cells to produce non-functional proteins, hindering the body’s antiviral defenses. This groundbreaking study by teams from prestigious Brazilian universities highlights potential targets for new COVID-19 treatments, [...]